ISN Africa Regional Board Webinar: SGLT2 inhibitors: a double gain for Nephrology
- 2 PM CET
The emergence of SGLT2 inhibitors (SGLT2i) has revolutionized the management of chronic kidney disease (CKD), offering nephrologists an invaluable tool to address the dual challenges of metabolic-cardiovascular risk and renal protection. This session will explore how SGLT2 inhibitors serve as a crucial step in delaying renal failure, particularly in CKD patients, while simultaneously reducing the broader spectrum of cardiovascular and metabolic risks. The discussion will highlight the significant impact of SGLT2 inhibitors in slowing CKD progression, their mechanisms of action, and evidence from pivotal clinical trials. Additionally, it will provide a deep dive into the multifaceted benefits of SGLT2 inhibition, addressing its role in managing metabolic derangements, cardiovascular comorbidities, and renal function decline. Finally, the session will examine the synergistic potential of GLP-1 receptor agonists (GLP1Ra) alongside SGLT2 inhibitors, focusing on combined strategies for optimizing outcomes in patients with CKD and cardiovascular risk. This session aims to provide attendees with a comprehensive understanding of SGLT2 inhibitors’ transformative role in nephrology, positioning them as a cornerstone therapy for CKD patients.
Learning objectives:
- Understand the Role of SGLT2 Inhibitors in CKD Management
- Explore the Broader Benefits of SGLT2 Inhibition
- Evaluate the Synergy Between SGLT2 Inhibitors and GLP-1 Receptor Agonists:
Moderators
Fatiu Arogundade (Nigeria)
Mohamed Salah (Egypt)
Speakers
Faiçal Jarraya (Tunisia)
Valerie Luyckx (Switzerland)
Nicola Wearne (South Africa)